DefescheJCGiddingSSHarada-ShibaM, et al.Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093.
2.
GiddingSSChampagneMAde FerrantiSD, et al.The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167–92.
3.
RaalFJSantosRD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–8.
4.
AkioyamenLTuJVGenestJ, et al.Cerebral and peripheral arterial disease risk in heterozygous familial hypercholesterolemia: a meta-analysis. Angiology. 2019;70(8):726–36.
5.
HuxleyRRHawkinsMHHumphriesSEKarpeFNeilHA. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke. 2003;34:22–5.
6.
Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893–6.
7.
HutterCMAustinMAHumphriesSE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol. 2004;160430–5.
8.
KroonAAAjubiNvan AstenWN, et al.The prevalence of peripheral vascular disease in familial hypercholesterolaemia. J Intern Med. 1995;238:451–9.
9.
PerhoniemiVGyllingHSalmenkiviK. Peripheral atherosclerosis in familial hypercholesterolaemia. J Intern Med. 1989;225:379–83.
10.
PereiraCMinameMHMakdisseMR, et al.Peripheral arterial disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 2015;242:174–8.
11.
BeliardSBoccaraFCariouB, et al.High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry. Atherosclerosis. 2018;277:334–40.
12.
BesselingJKindtIHofM, et al.Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 2014;233:219–23.
13.
WierzbickiASViljoenAViljoenS, et al.Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. Int J Clin Pract. 2018;72:e13242.
14.
WierzbickiASWattsGF. The hinterland of familial hypercholesterolaemia: what do we not know?Curr Opin Lipidol. 2015;26:475–83.
15.
StarrBJHadfieldGHuttenBA, et al.Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med. 2008;46:791–803.
16.
Cea SorianoLFowkesFGRJohanssonS, et al.Cardiovascular outcomes for patients with symptomatic peripheral artery disease: a cohort study in The Health Improvement Network (THIN) in the UK. Eur J Prev Cardiol. 2017;24:1927–37.
17.
Tunstall-PedoeHPetersSAEWoodwardM, et al.Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc. 2017;6:pii: e005967.
18.
BesselingJKasteleinJJDefescheJC, et al.Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313:1029–36.
19.
AlonsoRAndresEMataN, et al.Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982–9.
20.
GurdasaniDSjoukeBTsimikasS, et al.Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058–65.
21.
ClarkeREPadayacheeSTPrestonR, et al.Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart. 2013;99:175–80.
22.
SmildeTJvanWSWollersheimH, et al.Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–81.
23.
van WissenSSmildeTJde GrootE, et al.The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Eur J Cardiovasc Prev Rehabil. 2003;10:451–5.
24.
BonacaMPNaultPGiuglianoRP, et al.Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 inhibition in subjects With elevated risk). Circulation. 2018;137:338–50.
25.
WierzbickiASReynoldsTMViljoenA. An update on trials of novel lipid-lowering drugs. Curr Opin Cardiol. 2018;33:416–22.
